Compare American Superconductor Corporation (AMSC) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Superconductor Corporation vs DexCom, Inc. — how do they compare? American Superconductor Corporation trades at $35.49 (market cap $1.74B), while DexCom, Inc. trades at $74.97 (market cap $28.93B). The key difference: DexCom, Inc. is far larger — about 16.6× American Superconductor Corporation's market cap, and DexCom, Inc. is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| AMSC | DXCM | |
|---|---|---|
Market Cap | $1.74B | $28.93B |
Sector | Technology | Health |
52-Week High | $66.68 | $89.53 |
52-Week Low | $25.95 | $54.84 |
Enterprise Value | $1.61B | $27.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
DXCM trades at $74.96, up 2.66% today, with strong technical momentum as price approaches resistance near $76. The company demonstrates robust fundamentals with revenue growth from $2.9B in 2022 to $4.7B in 2025 and expanding net margins to 17.93%. Recent FDA clearance for pediatric Stelo CGM and positive CONNECT trial results support growth in the non-insulin diabetes market.
Outlook remains positive with 80% analyst buy ratings and $83.78 consensus target, though risks include GLP-1 drug competition and execution in expanding beyond insulin-dependent patients. Earnings beat expectations in three consecutive quarters, with Q2 2026 results anticipated July 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
